JD MBA - Blueprint Medicines Ex Chairman
| BPMCDelisted Stock | USD 129.46 0.11 0.09% |
Insider
JD MBA is Ex Chairman of Blueprint Medicines Corp
| Age | 51 |
| Phone | (617) 374-7580 |
| Web | https://www.blueprintmedicines.com |
Blueprint Medicines Management Efficiency
The company has return on total asset (ROA) of (0.0975) % which means that it has lost $0.0975 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4771) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities.Blueprint Medicines Corp currently holds 126.05 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Blueprint Medicines Corp has a current ratio of 5.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Blueprint Medicines' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Cedric MD | Apellis Pharmaceuticals | 53 | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| John Hunter | FibroGen | 61 | |
| John II | Ultragenyx | 59 | |
| Justin Klee | Amylyx Pharmaceuticals | 34 | |
| Ernie Meyer | Ultragenyx | 60 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| ShinSan Su | Agios Pharm | 69 | |
| Shauna Horvath | Amylyx Pharmaceuticals | N/A | |
| MD MBA | Amylyx Pharmaceuticals | 63 | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| Mr JD | FibroGen | N/A | |
| Barry Berkowitz | FibroGen | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Craig MD | Agios Pharm | 72 | |
| Enrique Conterno | FibroGen | 57 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Elias Kouchakji | FibroGen | 68 | |
| James MBA | Amylyx Pharmaceuticals | 58 | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0975 |
Blueprint Medicines Corp Leadership Team
Elected by the shareholders, the Blueprint Medicines' board of directors comprises two types of representatives: Blueprint Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Blueprint. The board's role is to monitor Blueprint Medicines' management team and ensure that shareholders' interests are well served. Blueprint Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Blueprint Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Becker MD, Chief Officer | ||
| Michael Landsittel, Interim Principal Accounting and Financial Officer and Sr. Director of Fin. | ||
| Dr MBA, Chief Officer | ||
| Kathryn MBA, CEO President | ||
| Ariel Hurley, Principal Accounting Officer | ||
| Tracey Esq, Chief VP | ||
| Christina Rossi, Chief Commercial Officer | ||
| Michael CPA, Chief Officer | ||
| Kathryn Haviland, Chief Business Officer | ||
| Christopher Murray, Senior Vice President Technical Operations | ||
| Debra DursoBumpus, Chief Officer | ||
| Alexis AM, CoFounder Director | ||
| JD MBA, Ex Chairman | ||
| Jenna Cohen, Director Relations | ||
| Christina MBA, Chief Officer | ||
| Fouad MD, President Development | ||
| Julian Baker, Senior Affairs | ||
| Georg MD, Senior International | ||
| Sherwin Sattarzadeh, Chief Officer |
Blueprint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Blueprint Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0975 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 8.25 B | ||||
| Shares Outstanding | 64.58 M | ||||
| Shares Owned By Insiders | 0.80 % | ||||
| Shares Owned By Institutions | 99.20 % | ||||
| Number Of Shares Shorted | 3.68 M | ||||
| Price To Earning | 7.93 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Blueprint Stock
If you are still planning to invest in Blueprint Medicines Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Blueprint Medicines' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |